Compare Organon & Co. Common Stock (OGN) vs O'Reilly Automotive Inc. Common Stock (ORLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs O'Reilly Automotive Inc. Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while O'Reilly Automotive Inc. Common Stock trades at $87.34 (market cap $69.59B). The key difference: O'Reilly Automotive Inc. Common Stock is far larger — about 19.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while O'Reilly Automotive Inc. Common Stock pays none. Which is the better fit depends on your goals.
| OGN | ORLY | |
|---|---|---|
Market Cap | $3.62B | $69.59B |
Volume | 2,892,999 | 3,367,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $102.12 |
52-Week Low | $5.70 | $82.73 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $11.04B | $78.92B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
O'Reilly Automotive (ORLY) trades at $86.03, down 0.72% on the day, amid a mixed technical picture with a bullish overall signal but bearish moving averages. The company reported strong fundamentals with 2025 revenue of $17.78 billion and net income of $2.54 billion, maintaining a robust net income margin of 14.27%. Recent news highlights its defensive positioning in the auto parts market and upcoming Q3 2026 earnings release on October 28, 2026.
The outlook remains positive with a consensus price target of $106.09, implying significant upside. Key opportunities include resilient demand from an aging vehicle fleet and expansion plans in Mexico. Risks involve competitive pressures and potential macroeconomic headwinds affecting consumer spending on auto repairs. Analyst sentiment is strongly bullish with 59.57% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About O'Reilly Automotive Inc. Common Stock
O'Reilly Automotive sells automotive aftermarket parts, tools, supplies, equipment, and accessories. It serves both professional service providers and do-it-yourself customers through its store network.
Read more on ORLY →
